NCT06425055 - Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

July 21, 2025

Study Completion Date

October 13, 2025

Conditions

Alport Syndrome

Interventions

DRUG

Vonafexor

"* One tablet of a low dose of vonafexor QD from Day 1 to Week 4~* One tablet of a medium dose of vonafexor QD from Week 5 to Week 8~* One tablet of a high dose of vonafexor QD from Week 9 to Week 24"

Trial Locations (13)

28040

Fundacion Jimenez Diaz, Madrid

30120

Hospital Virgen de la Arrixaca, El Palmar

33076

Pr Claire Rigothier - CHU De Bordeaux, Bordeaux

34090

Dr Moglie Le Quintrec - Hopital Lapeyronie, Montpellier

35294

Dr Eric Wallace - University of Alabama, Birmingham

44195

Dr James Simon - Cleveland Clinic Foundation, Cleveland

60521

Dr Suneel Udani - NANI Research, Hinsdale

63110

Dr Tingting Li - Washington University, St Louis

75015

Pr. Bertrand Knebelmann - Necker Enfants Malades, Paris

75126

Dr Ankit Mehta - Renal Disease Research Institute, Dallas

83703

Dr Arnold Silva - Boise Kidney & Hypertension, Boise

90095

Dr Anjay Rastogi - UCLA Health, David Geffen School of Medicine, Los Angeles

08025

Fundacio Puigvert, Barcelona